MicroRNA-155 is upregulated in MLL-rearranged AML but its absence does not affect leukemia development

被引:17
作者
Schneider, Edith [1 ]
Staffas, Anna [2 ,3 ]
Roehner, Linda [1 ]
Krowiorz, Kathrin [1 ]
Heuser, Michael [4 ]
Doehner, Konstanze [1 ]
Bullinger, Lars [1 ]
Doehner, Hartmut [1 ]
Fogelstrand, Linda [2 ,3 ]
Rouhi, Arefeh [1 ]
Kuchenbauer, Florian [1 ]
Palmqvist, Lars [2 ,3 ]
机构
[1] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany
[2] Univ Gothenburg, Sahlgrenska Acad, Inst Biomed, Dept Clin Chem & Transfus Med, Gothenburg, Sweden
[3] Sahlgrens Univ Hosp, Dept Clin Chem, Gothenburg, Sweden
[4] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany
基金
加拿大健康研究院;
关键词
MIR-155;
D O I
10.1016/j.exphem.2016.08.012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
MicroRNA-155 (miR-155) is an oncogenic miRNA upregulated in various tumor types and leukemias and has been suggested as a potential drug target. Based on our previous work detecting high miR-155 levels in response to Meisl overexpression in a murine Hox leukemia model, we show here the relationship among HOXA9, MEIS1, and miR-155 levels in MLL-translocated acute myeloid leukemia (AML) patients. Using mouse bone marrow cells transformed by MLL-fusion genes expressing graduated levels of Meisl, we show a positive correlation between miR-155 and Meisl. However, using a miR-155-knockout mouse model, we show that the absence and the depletion of miR-155 have no effect on leukemia formation or progression. We also show for the first time that miR-155 levels are correlated with MLL translocations, but that miR-155 expression is dispensable for the formation of AML and has no effect on leukemia progression. Copyright (C) 2016 ISEH-International Society for Experimental Hematology. Published by Elsevier Inc.
引用
收藏
页码:1166 / 1171
页数:6
相关论文
共 15 条
[1]   MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia [J].
Gentner, Bernhard ;
Pochert, Nicole ;
Rouhi, Arefeh ;
Boccalatte, Francesco ;
Plati, Tiziana ;
Berg, Tobias ;
Sun, Su Ming ;
Mah, Sarah M. ;
Mirkovic-Hoesle, Milijana ;
Ruschmann, Jens ;
Muranyi, Andrew ;
Leierseder, Simon ;
Argiropoulos, Bob ;
Starczynowski, Daniel T. ;
Karsan, Aly ;
Heuser, Michael ;
Hogge, Donna ;
Camargo, Fernando D. ;
Engelhardt, Stefan ;
Doehner, Hartmut ;
Buskeg, Christian ;
Jongen-Lavrencic, Mojca ;
Naldini, Luigi ;
Humphries, R. Keith ;
Kuchenbauer, Florian .
EXPERIMENTAL HEMATOLOGY, 2015, 43 (10) :858-868
[2]  
Gentner B, 2009, NAT METHODS, V6, P63, DOI [10.1038/NMETH.1277, 10.1038/nmeth.1277]
[3]   Next Generation Sequencing and Functional Analysis of Mirna Expression in Acute Myeloid Leukemia Patients with Different FLT3 Mutations: Block of MiR-155 in FLT3-ITD Driven AML Leads to Downregulation of Myeloid Blasts in Vivo [J].
Gerloff, Dennis ;
Wurm, Alexander Arthur ;
Hartmann, Jens-Uwe ;
Hilger, Nadja ;
Mueller, Anne-Marie ;
Katzerke, Christiane ;
Braeuer-Hartmann, Daniela ;
Namasu, Carolina Yaeko ;
Cross, Michael ;
Schwind, Sebastian ;
Krohn, Knut ;
Fricke, Stephan ;
Niederwieser, Dietger ;
Behre, Gerhard .
BLOOD, 2015, 126 (23)
[4]   HOXA9 regulates miR-155 in hematopoietic cells [J].
Hu, Yu-Long ;
Fong, Stephen ;
Largman, Corey ;
Shen, Wei-Fang .
NUCLEIC ACIDS RESEARCH, 2010, 38 (16) :5472-5478
[5]   Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia [J].
Khalife, J. ;
Radomska, H. S. ;
Santhanam, R. ;
Huang, X. ;
Neviani, P. ;
Saultz, J. ;
Wang, H. ;
Wu, Y-Z ;
Alachkar, H. ;
Anghelina, M. ;
Dorrance, A. ;
Curfman, J. ;
Bloomfield, C. D. ;
Medeiros, B. C. ;
Perrotti, D. ;
Lee, L. J. ;
Lee, R. J. ;
Caligiuri, M. A. ;
Pichiorri, F. ;
Croce, C. M. ;
Garzon, R. ;
Guzman, M. L. ;
Mendler, J. H. ;
Marcucci, G. .
LEUKEMIA, 2015, 29 (10) :1981-1992
[6]   In-depth characterization of the microRNA transcriptome in a leukemia progression model [J].
Kuchenbauer, Florian ;
Morin, Ryan D. ;
Argiropoulos, Bob ;
Petriv, Oleh I. ;
Griffith, Malachi ;
Heuser, Michael ;
Yung, Eric ;
Piper, Jessica ;
Delaney, Allen ;
Prabhu, Anna-Liisa ;
Zhao, Yongjun ;
McDonald, Helen ;
Zeng, Thomas ;
Hirst, Martin ;
Hansen, Carl L. ;
Marra, Marco A. ;
Humphries, R. Keith .
GENOME RESEARCH, 2008, 18 (11) :1787-1797
[7]  
Kuchenbauer F, 2005, HAEMATOLOGICA, V90, P1617
[8]   Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells [J].
Kuchenbauer, Florian ;
Mah, Sarah M. ;
Heuser, Michael ;
McPherson, Andrew ;
Rueschmann, Jens ;
Rouhi, Arefeh ;
Berg, Tobias ;
Bullinger, Lars ;
Argiropoulos, Bob ;
Morin, Ryan D. ;
Lai, David ;
Starczynowski, Daniel T. ;
Karsan, Aly ;
Eaves, Connie J. ;
Watahiki, Akira ;
Wang, Yuzhuo ;
Aparicio, Samuel A. ;
Ganser, Arnold ;
Krauter, Juergen ;
Doehner, Hartmut ;
Doehner, Konstanze ;
Marra, Marco A. ;
Camargo, Fernando D. ;
Palmqvist, Lars ;
Buske, Christian ;
Humphries, R. Keith .
BLOOD, 2011, 118 (12) :3350-3358
[9]   Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients [J].
Marcucci, Guido ;
Maharry, Kati S. ;
Metzeler, Klaus H. ;
Volinia, Stefano ;
Wu, Yue-Zhong ;
Mrozek, Krzysztof ;
Nicolet, Deedra ;
Kohlschmidt, Jessica ;
Whitman, Susan P. ;
Mendler, Jason H. ;
Schwind, Sebastian ;
Becker, Heiko ;
Eisfeld, Ann-Kathrin ;
Carroll, Andrew J. ;
Powell, Bayard L. ;
Kolitz, Jonathan E. ;
Garzon, Ramiro ;
Caligiuri, Michael A. ;
Stone, Richard M. ;
Bloomfield, Clara D. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (17) :2086-2093
[10]   Preclinical Results Supporting Therapeutic Development of Mrg-106, an Oligonucleotide Inhibitor of Mir-155, in CTCL [J].
Seto, Anita G. ;
Beatty, Xuan T. ;
Pestano, Linda A. ;
Dickinson, Brent A. ;
Warren, Marshelle S. ;
Rodman, David M. ;
Jackson, Aimee L. .
BLOOD, 2015, 126 (23)